arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Denali Therapeutics Inc.

DNLI
$20.45 ▼ -1.16 (-5.34%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
40 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Bearish
auto_awesome

Analytical Summary

Denali Therapeutics Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $3.8B
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -12.3%
FCF / Share $-0.52
Trailing P/E
Price / Book 3.9x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

40-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$3.60M
Net Income Profit after all expenses
$-127.55M
↓ -2.8%
Operating Margin Operating profit as % of sales
58.0%
↑ +116.9%
FCF / Share Free cash flow per share
$-0.52
↑ +27.1%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
17
Cash Quality
56

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 11 years · 40 quarters